| Autor: |
Nirogi, Ramakrishna, Mohammed, Abdul Rasheed, Shinde, Anil K., Ravella, Srinivasa Rao, Bogaraju, Narsimha, Subramanian, Ramkumar, Mekala, Venkat Reddy, Palacharla, Raghava Choudary, Muddana, Nageswararao, Thentu, Jagadeesh Babu, Bhyrapuneni, Gopinadh, Abraham, Renny, Jasti, Venkat |
| Zdroj: |
Journal of Medicinal Chemistry; March 2020, Vol. 63 Issue: 6 p2833-2853, 21p |
| Abstrakt: |
A series of chemical optimizations guided by in vitro affinity at the α4β2 receptor in combination with selectivity against the α3β4 receptor, pharmacokinetic evaluation, and in vivo efficacy in a forced swim test resulted in identification of 3-(6-chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (9h, SUVN-911) as a clinical candidate. Compound 9his a potent α4β2 receptor ligand with a Kivalue of 1.5 nM. It showed >10 μM binding affinity toward the ganglionic α3β4 receptor apart from showing selectivity over 70 other targets. It is orally bioavailable and showed good brain penetration in rats. Marked antidepressant activity and dose-dependent receptor occupancy in rats support its potential therapeutic utility in the treatment of depression. It does not affect the locomotor activity at doses several folds higher than its efficacy dose. It is devoid of cardiovascular and gastrointestinal side effects. Successful long-term safety studies in animals and phase-1 evaluation in healthy humans for safety, tolerability, and pharmacokinetics paved the way for its further development. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
